ClinicalTrials.gg
CompletedNCT03222362PPVUpdated Jul 19, 2017

Pars Plana Vitrecromy in Patients Aged 85 Years and Above

An observational study in Vitreous Injury, Retinal Detachment and Age Related Macular Degeneration, sponsored by Tel Aviv Medical Center. Completed. Open to participants aged 85 Years and older. Per ClinicalTrials.gov, last updated 2017-07-19.

Sponsored by Tel Aviv Medical Center · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
120
Ages
85 Years and older
Sex
All
01

Study summary

We reviewed the records of 120 consecutive patients (male and female), aged 85 years and above, who underwent pars plana vitrecromy in the Tel Aviv Medical Center during the years 01/01/2006 - 31/12/2013, and were followed by physicians in the ophthalmology department in the center until December 2015.

Read the detailed description

We reviewed the records of 120 consecutive patients (male and female), aged 85 years and above, who underwent pars plana vitrecromy in the Tel Aviv Medical Center during the years 01/01/2006 - 31/12/2013, and were followed by physicians in the ophthalmology department in the center until December 2015. We will be measuring visual acuity, intra-ocular pressure, demographics (age, gender), indication for surgery, ocular co-morbidities, surgical parameters (time of surgery, type of anesthesia - general or local, type of suture), and intraoperative and postoperative complications.

Primary outcome - visual acuity will be measured at base line, after 1 week, 1 month, 3 months, 6 months / last follow up (until December 2015). visual acuity will be determined by a standardized chart test (Snellen chart). For statistical analysis, all VA values were converted to logMAR scale. According to Holladay and the University of Freiburg study group results, blindness was set at 0.00125/2.9 (decimal/logMAR), light perception at 0.0025/2.6, hand movements at 0.005/2.3 and counting fingers at 0.014/1.85. Data will be analyzed using SPSS software. A p-value of 0.05 will be considered statistically significant and t-tests analysis will be used to compare between means.

Secondary outcomes - demographics, Indication for surgery, ocular co morbidities will be measured at baseline. Surgical parameters and intraoperative complications will be measured at 1 week. Postoperative complications will be measured during follow up after 1 week, 1 month, 3 months, 6 months / last follow up (until December 2015).

Complications will be measured by examination of intraocular pressure, slit-lamp and fundus (Ophthalmoscopic Exam).

02

Conditions studied

  • Vitreous Injury
  • Retinal Detachment
  • Age Related Macular Degeneration

Keywords

  • retinal detachment
  • trauma
  • age related macular degeneration
03

In context

Retinal Detachment

200 studies on the registry are indexed under Retinal Detachment; 30 are open to participants now.

This study's enrollment of 120 is above the median of 60 across 58 observational studies indexed under Retinal Detachment.

Browse Retinal Detachment studies →

Lead sponsor

Tel Aviv Medical Center is the lead sponsor of 10 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
85 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients aged 85 years and above, who underwent pars plana vitrecromy in the Tel Aviv Medical Center during the years 01/01/2006 - 31/12/2013

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients aged 85 years and above, who underwent pars plana vitrecromy in the Tel Aviv Medical Center during the years 01/01/2006 - 31/12/2013

Exclusion criteria

Exclusion Criteria:

ANy other

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
120 participants (actual)
Patient registry
No

Groups and cohorts

  • patients 85 years and above

    120 consecutive patients (male and female), aged 85 years and above, who underwent pars plana vitrecromy in the Tel Aviv Medical Center during the years 01/01/2006 - 31/12/2013, and were followed by physicians in the ophthalmology department in the center until December 2015.

    Other: Surgery

Interventions

  • OtherSurgery
06

What researchers measure

Primary outcomes

  1. visual acuity

    visual acuity in Snellen chart

    Time frame: study entry until December 2015 .

Secondary outcomes

  1. Postoperative complications

    Postoperative complications will be measured during follow up after 1 week, 1 month, 3 months, 6 months / last follow up

    Time frame: study entry until December 2015 .

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2006 to primary completion in Dec 2013, 95 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2017
First posted
Jul 19, 2017
StartActual
Jan 1, 2006
Primary completionActual
Dec 31, 2013
CompletionActual
Dec 31, 2015
Last update
Jul 19, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 19, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03222362
Lead sponsor
Tel Aviv Medical Center
Responsible party
Adiel Barak (Head Of vitrerretinal service, Tel Aviv Medical Center) — Principal investigator
First posted
Jul 19, 2017
Start date
Jan 1, 2006
Primary completion
Dec 31, 2013
Completion
Dec 31, 2015
Last update
Jul 19, 2017

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion